Screening is a test to detect early disease or risk factors for disease in large numbers of apparently healthy individuals. In medicine, it is checking for disease when there are no symptoms.
-
Dr. Oliver Kepp will be presenting on:Immunogenic cell death fingerprinting utilizing a high-throughput screening approachThe strategy of immunogenic cell death fingerprinting has been design...
The era of omics has ushered in the hope for personalized medicine. Proteomic and genomic strategies that allow unbiased identification of genes and proteins and their post-transcriptional a...
Many drugs currently used for anti-cancer therapy demonstrate significant inter-individual variability that cannot be normalized using body weight or body surface area. There is an increasing...
The effective implementation of personalised cancer therapeutic regimens depends on the successful identification and translation of informative biomarkers to aid clinical decision-making. An...
AUC sedimentation velocity (SV) has a longstanding reputation as being the gold standard for the matrix free quantification of aggregates in biopharmaceuticals. The continuous c(S) ...
Protein-protein interactions and allosterically regulated enzymes have been challenging but important targets for probe- and drug discovery. We and others have found that fragment-based lead...
Heptares Therapeutics is a structure based drug discovery and development company which uses it StaR technology to enable X-ray structures, fragment screening and other biophysical techniques...
Macrocycles offer a new structural class that has the potential to address challenging protein-protein interaction targets and still present attractive drug-like properties including cell mem...
Accurate and timely diagnosis of rejection and infection is essential for long-term survival of solid-organ transplant recipients. We evaluated the performance a novel test to monitor rejecti...